Sermorelin Legit

REFERENCE REGISTER / VERIFIABLE SOURCES

Sermorelin references.

Every study cited across this site, with PMID and DOI for verification. Each datum on the other pages traces back to one of these entries.

Back to the researchThe approved pediatric indication

How to read this list

The numbered list below corresponds to the inline [N] markers throughout the site. Each entry carries the full citation, a DOI where one exists, and a PubMed (PMID) link so any claim can be checked against its source. Where a finding is attributed to the stabilized GHRH analog tesamorelin rather than to sermorelin itself, the site says so in the text — the citation is the same regardless.

  1. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. ↗
  2. Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. ↗
  3. Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. ↗
  4. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. ↗
  5. Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. ↗
  6. Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. (NCT00257712) ↗
  7. Hümmelink R, et al. Intranasal administration of growth hormone-releasing hormone(1-29)-NH2 in children with growth hormone deficiency: effects on growth hormone secretion and growth. Acta Paediatr Suppl. 1993;388:23-6; discussion 27. ↗
  8. Grunt JA, et al. Effects of long-term growth hormone releasing hormone 1-29 in significantly short children. Acta Paediatr. 1995;84:631-3. ↗
  9. Tuilpakov AN, et al. Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature. Metabolism. 1995;44:1199-204. ↗
  10. Hernández M, et al. Subcutaneous treatment with growth hormone-releasing hormone for short stature. Horm Res. 1988;30:252-7. ↗
  11. Ko FY, Chen WP, Lin CY. Defective response of plasma growth hormone to growth hormone releasing factor in growth hormone deficient children. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1992;33:243-50. ↗
  12. Bagno L, et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(13):10846-10859. ↗
  13. Thomas A, et al. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Anal Bioanal Chem. 2016;408(13):3457-3464. ↗
  14. Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. ↗
  15. Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. ↗